Status:
ACTIVE_NOT_RECRUITING
A Phase 1 Study of Mosliciguat in Healthy, Adult Males
Lead Sponsor:
Pulmovant, Inc.
Conditions:
Healthy Volunteer
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
This is a single-center, Phase 1, open-label, 3-period, fixed-sequence study to investigate the bioavailability, absorption, metabolism, excretion and the safety of mosliciguat administered to healthy...
Eligibility Criteria
Inclusion
- Participants willing and able to provide informed consent.
- Considered to be in good health by the Investigator, as determined by medical history, physical examination, vital sign measurements, 12 lead electrocardiogram (ECG), and laboratory test results.
Exclusion
- History or presence of any condition (e.g., chronic diarrhea, urinary incontinence), or prior surgery (e.g., gastric bypass) that, in the opinion of the Investigator, poses a significant risk to participant safety and/or achievement of study objectives
- History or presence of COPD, moderate or persistent asthma, other chronic lung disease, or chronic respiratory condition within the last 5 years
- Acute or recent respiratory infection symptoms not resolved at least 3 days prior to Period 1 check-in.
Key Trial Info
Start Date :
June 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2026
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT07185321
Start Date
June 10 2025
End Date
May 1 2026
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pharmaron
Baltimore, Maryland, United States, 21201